[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastritis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,70,92,117,145,168,196,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637972","phase-4-vonoprazan-high-dose-dual-vs-levofloxacin-concomitant-100637972",false,"NCT07624422","Vonoprazan High-Dose Dual VS Levofloxacin Concomitant","Efficacy and Safety of Vonoprazan High-Dose Dual Therapy Compared to Levofloxacin Concomitant Therapy for H. Pylori Eradication: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years (adjust upper limit as needed)\n* Confirmed Helicobacter pylori infection by at least one of the following: positive urea breath test, rapid urease test, histopathology, or stool antigen test\n* Treatment-naïve for H. pylori (no prior eradication therapy) - OR - prior treatment failure (specify if rescue therapy)\n* Willing and able to provide written informed consent\n* Willing to adhere to the 14-day treatment regimen and follow-up visits\n* For women of childbearing potential: negative pregnancy test and agreement to use effective contraception during the treatment period\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity to vonoprazan, amoxicillin, clarithromycin, metronidazole, or any other penicillin\u002Fcephalosporin\n* Previous H. pylori eradication therapy (if study is for first-line treatment)\n* Active gastrointestinal bleeding or perforation\n* Severe liver disease (Child-Pugh class B or C) or severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnancy or breastfeeding\n* Concurrent use of medications with significant drug-drug interactions (e.g., warfarin, phenytoin, digoxin, atazanavir, rilpivirine)\n* Malignancy or any life-threatening condition with life expectancy \\\u003C 6 months\n* Participation in another interventional trial within 30 days prior to enrollment\n* Any condition that, in the investigator's opinion, precludes safe participation or adherence to the protocol","ALL","18 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a randomized controlled trial comparing the efficacy and safety of two vonoprazan-based regimens: high-dose dual therapy (vonoprazan plus a single antibiotic) versus triple therapy (vonoprazan plus two antibiotics) for the treatment of H. pylori infection).\n\nParticipants will be randomly assigned to receive either regimen for 14 days. The primary outcome is eradication rate , and secondary outcomes include adverse events and treatment adherence.",[27,28,29],"Helicobacter Pylori Infection","Peptic Ulcer Disease","Gastritis",[27,31],"Vonoprazan","NOT_YET_RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":21},"2026-11-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Damascus Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100639619","phase-4-phase-4-study-of-sto-m-tab-in-acute-or-chronic-gastritis-100639619","NCT07631065","Phase 4 Study of Sto M Tab. in Acute or Chronic Gastritis","A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Sto M Tab. in Patients With Acute or Chronic Gastritis","Inclusion Criteria:\n\n1. Male or female adults aged 19 to 75 years at the time of screening.\n2. Participants diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy performed within 7 days prior to randomization (Visit 2), with at least one gastric erosion confirmed. Erosions of the esophagus and duodenum are excluded.\n3. Female participants of childbearing potential or male participants who agree to maintain sexual abstinence or use appropriate contraceptive methods during the study period and for 2 weeks after the last administration of the investigational product. Periodic abstinence, such as calendar, ovulation, symptothermal, or post-ovulation methods, is not considered an acceptable contraceptive method.\n4. Participants who voluntarily provide written informed consent to participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Participants with any of the following lesions confirmed or accompanied by upper gastrointestinal endoscopy at screening (Visit 1): active or healing peptic ulcer; reflux esophagitis; Barrett's esophagus greater than 3 cm; gastroesophageal varices; esophageal stricture; or other clinically relevant lesions. Participants with ulcer scars may be enrolled.\n2. Participants who have a history of gastric acid secretion-inhibiting surgery or gastric or esophageal surgery at screening (Visit 1).\n3. Participants who have been diagnosed with or have a history of Zollinger-Ellison syndrome at screening (Visit 1).\n4. Participants with inflammatory bowel disease, such as Crohn's disease, ulcerative colitis, or intestinal Behcet's disease; primary esophageal motility disorder; or pancreatitis at screening (Visit 1).\n5. Participants with a history of malignancy within 5 years prior to screening (Visit 1). However, participants who have been completely treated and have had no recurrence for at least 5 years may be enrolled at the investigator's discretion. Participants with gastrointestinal malignancy are excluded regardless of the time since diagnosis. Participants with basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ of other sites may be enrolled at the investigator's discretion if they have been completely treated and have had no recurrence for at least 3 years.\n6. Participants with current or prior thrombotic disease at screening (Visit 1), such as cerebral thrombosis, myocardial infarction, thrombophlebitis, or venous thrombosis.\n7. Participants diagnosed with disseminated intravascular coagulation at screening (Visit 1).\n8. Participants with concomitant hepatic, renal, cardiac, pulmonary, hematologic, or other diseases that, in the investigator's judgment, may affect the efficacy or safety evaluations.\n9. Participants with current or prior lipid metabolism disorders at screening (Visit 1), such as hyperlipidemia or diabetic hyperlipidemia, or participants who require cautious administration of lipid nutritional products. However, participants whose condition is adequately controlled with medication may be enrolled at the investigator's discretion.\n10. Participants with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n11. Participants with a history of hypersensitivity to soybean, peanut, or soybean oil.\n12. Participants with a history of hypersensitivity to any component of the investigational products, such as tartrazine.\n13. Participants with clinically significant psychiatric disease at screening (Visit 1).\n14. Participants who meet any other exclusion criteria related to prior or concomitant medications specified in the protocol.","19 Years","75 Years",{"count":55,"type":21},470,[24],"This Phase 4, multicenter, randomized, double-blind, active-controlled, non-inferiority study aims to evaluate the non-inferiority of Stoem Tab. compared to Stillen Tab. (Dong-A ST Co., Ltd.) in patients with acute or chronic gastritis. Participants will receive either Stoem Tab. or Stillen Tab. for 2 weeks. The primary outcome is the effective rate of gastric mucosal erosion at Week 2, assessed by upper gastrointestinal endoscopy and evaluated by an independent reviewer, defined as the proportion of participants achieving at least a 50% improvement in erosion score compared to baseline.",[29,59,60],"Acute Gastritis","Chronic Gastritis",{"date":62,"type":36},"2026-06-05",{"date":64,"type":21},"2026-06",{"date":66,"type":21},"2028-02",{"name":68,"class":69},"Mather's Pharm. Co., Ltd.","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":4},"100622563","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-and-safety-of-ad-229-compared-to-ad-2291-in-healthy-adults-100622563","NCT07385248","A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults","An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,{"count":79,"type":21},28,[81],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.",[29],"2026-02-26",{"date":86,"type":36},"2026-02-27",{"date":88,"type":21},"2026-04",{"date":64,"type":21},{"name":91,"class":69},"Addpharma Inc.",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":44},"100603657","phase-4-saccharomyces-boulardii-combined-with-bismuth-quadruple-therapy-for-helicobacter-pylori-rescue-treatment-100603657","NCT07139366","Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18\\~75, both gender.\n* Patients who had failed H.pylori eradication therapies .\n* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.\n\nExclusion Criteria:\n\n* Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.\n* Contraindications to study drugs.\n* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.\n* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \\[13C\\] urea breath test), antibiotics or bismuth complexes (more than 3 times \u002F1 month before screening).\n* Pregnant or lactating women.\n* Underwent upper gastrointestinal Surgery.\n* Dysphagia.\n* Evidence of bleeding or iron efficiency anemia.\n* A history of malignancy.\n* Drug or alcohol abuse history in the past 1 year.\n* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg\u002Fd).\n* Mental disorder.\n* Enrolled in other clinical trials in the past 3 months.\n* Refuse to sign informed consent.",{"count":100,"type":21},1248,[24],"This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.",[29,104,27,105,106],"Dyspepsia","Gastric Cancer","Peptic Ulcer","RECRUITING","2025-11-30",{"date":110,"type":36},"2025-12-02",{"date":112,"type":36},"2025-10-28",{"date":114,"type":21},"2026-09",{"name":116,"class":43},"Yongquan Shi",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100599765","comparison-of-the-sensitivity-of-pcle-and-pathological-biopsy-before-esd-100599765","NCT07088744","Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD","Comparison of the Sensitivity of Probe-based Confocal Laser Endomicroscopy and Pathological Biopsy Before Endoscopic Submucosal Dissection","Inclusion Criteria:\n\n* patients aged 18 to 85 years who were scheduled for endoscopic submucosal dissection due to early-stage gastric cancer were consecutively enrolled.\n\nExclusion Criteria:\n\n* Severe cardiac or pulmonary dysfunction, impaired renal function, coagulopathy, pregnancy or lactation, allergy to fluorescein, and inability to provide informed consent.",{"count":125,"type":21},169,"OBSERVATIONAL","Pathological biopsy before endoscopic submucosal dissection (ESD) the gastric lesion plays an important role in differentiating the pathological nature of the lesion and guiding treatment decisions. However, due to the influence of the materials used, the sensitivity of pathological biopsy is not satisfactory. Confocal Laser Endomicroscopy (CLE) is a technology that integrates a confocal microscope into an endoscope. It enables the acquisition of high-resolution microscopic images of the mucosal layer in real-time (with a magnification of up to 1000 times), and it is an optical biopsy technique. It has unique value in the determination of the pathological nature of gastric lesions. The main purpose of this study is to compare the sensitivity of pathological biopsy and CLE in differentiating the pathological nature of gastric lesions.",[129,130,131,29],"Gastric Cancer (Diagnosis)","Gastric High-grade Intraepithelial Neoplasia","Gastric Low-grade Intraepithelial Neoplasia",[133,134],"Confocal Laser Endomicroscopy","pathological biopsy","2025-07-19",{"date":137,"type":36},"2025-07-28",{"date":139,"type":21},"2025-07-30",{"date":141,"type":21},"2025-09-15",{"name":143,"class":43},"Changhai Hospital",4,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":152,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":44},"100588982","efficacy-and-safety-of-fexuclue-tab-in-patients-with-acute-or-chronic-gastritis-100588982","NCT06948487","Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis","A Prospective, Multi-center, Observational Study on the Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis","Inclusion Criteria:\n\n* Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.\n* Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.\n* Subjects who present with at least one subjective symptom requiring medical treatment\n* Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.\n\nExclusion Criteria:\n\n* Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.\n* Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.",{"count":153,"type":21},12000,"This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.",[29],[157,158],"Acute","Chronic","2025-07-14",{"date":161,"type":36},"2025-07-17",{"date":163,"type":36},"2025-06-17",{"date":165,"type":21},"2027-06-03",{"name":167,"class":69},"Daewoong Pharmaceutical Co. LTD.",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":77,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":178,"conditions":179,"keywords":183,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100595477","a-cohort-study-of-mobile-capsule-gastroscopy-for-gastric-pathologies-screening-100595477","NCT07032961","A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening","Screening for Gastric Pathologies in Elderly and High-Risk Populations Using a Mobile Capsule Gastroscopy System: a Prospective, Multicenter, Population Based Cohort Study","Inclusion Criteria:\n\n1.Provision of written informed consent; 2.Participants of the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality', the following are the criteria for inclusion in this public welfare programme:\n\n1. Elderly cohort: Permanent residents of Guangzhou aged ≥60 years who have not undergone specialized gastric disease screening in the past three years;\n2. Or high-risk cohort: Individuals aged ≥45 years who meet at least one of the following risk criteria:\n\n   1. History of Helicobacter pylori infection (positive ¹³C\u002F¹⁴C urea breath test);\n   2. Prior diagnosis of chronic atrophic gastritis, gastric ulcer, neoplastic gastric polyps, hypertrophic gastritis, or pernicious anemia;\n   3. Family history of gastric cancer (first-degree relative with a confirmed diagnosis);\n   4. Long-term high-salt diet, smoking history (≥20 pack-years), or heavy alcohol consumption (100 mL of distilled spirits\u002Fday).\n\nExclusion Criteria:\n\n1. Not considered by the investigator to be suitable for participation in this study.\n2. Meets the exclusion criteria of the Public Welfare Programme. Individuals will be excluded if they meet any of the following conditions:\n\n(1)Known allergy to medical polymer materials; (2)Psychiatric disorders that interfere with procedural cooperation; (3)Pregnancy or lactation; (4)Severe systemic comorbidities (e.g., cardiovascular, respiratory, neurological diseases) affecting examination tolerance; (5)Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or gastrointestinal diverticulosis; (6)Known or suspected gastrointestinal malformations, obstructions, strictures, or fistulas; (7)Clinically significant dysphagia; (8)Acute abdominal symptoms (e.g., pain, vomiting, suspected bowel obstruction, or severe constipation); (9)History of major gastrointestinal surgery (e.g., esophagogastrostomy, gastrojejunostomy); (10)Physical debilitation precludes postural changes or concurrent severe illness; (11)Medically ineligible for abdominal procedures or refusal to undergo them; (12)Deemed unsuitable for MCG by the investigator; (13)Refusal to provide informed consent; (14)Any other condition judged by the investigator to make the individual unsuitable for study participation.","45 Years",{"count":177,"type":21},10000,"The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations.\n\nThe main question it aims to answer is:\n\nCan MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers?\n\nParticipants will:\n\nEpidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.",[29,180,181,105,182],"Gastric Dysplasia","Gastric Ulcer","Gastric Mass",[184,185,186],"Capsule Endoscopy","Prospective Study","screening","2025-07-03",{"date":189,"type":36},"2025-07-04",{"date":191,"type":36},"2025-06-24",{"date":193,"type":21},"2030-10-31",{"name":195,"class":43},"Nanfang Hospital, Southern Medical University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100581291","capsule-gastric-endoscopy-for-gastric-disease-screening-in-simulated-home-scenarios-100581291","NCT06848400","Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","A Multicenter, Prospective Study of Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","Inclusion criteria\n\n1. Aged 18 years or older.\n2. Individuals meeting the following criteria:\n\n   i. Healthy volunteers; ii. Suspected presence of gastrointestinal diseases, with one or more of the following clinical symptoms: abdominal pain, nausea, vomiting, hematemesis, black or bloody stools, loss of appetite, bloating, or indigestion; iii. Follow-up of gastric lesions post-endoscopic resection.\n3. Willing to participate voluntarily in the clinical trial and provide written informed consent.\n4. Capable of communicating with researchers and complying with trial requirements.\n\nExclusion criteria\n\n1. Pregnant individuals.\n2. Individuals at high risk of gastrointestinal obstruction, including those identified as being at risk of gastrointestinal stenosis based on the Gastrointestinal Stenosis Assessment Form, those in whom gastrointestinal obstruction cannot be clinically excluded, or individuals with a history of gastrointestinal surgery, severe motor dysfunction, or pseudobulbar palsy.\n3. Individuals with swallowing dysfunction.\n4. Individuals deemed unfit for surgery or unwilling to undergo any surgical procedures.\n5. Participants who are unable to comprehend and\u002For comply with physician instructions during the examination.\n6. Individuals with other medical risks that contraindicate the use of a capsule gastric endoscopy system, or those deemed unsuitable for participation in this study at the discretion of the investigator.",{"count":204,"type":21},482,[206],"NA","The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities. It will also compare the diagnostic accuracy and time efficiency of AI-assisted interpretation versus manual reading of ACG data. The main questions it aims to answer are:\n\nWhat is the diagnostic accuracy of the ACG system, using conventional esophagogastroduodenoscopy (EGD) as a standard of reference?\n\nDoes AI-assisted ACG reading improve diagnostic accuracy or reduce reading time compared to manual ACG video reading?\n\nResearchers will compare ACG results to conventional EGD findings (standard of reference) to determine if ACG can serve as a reliable method for UGI disease detection in home scenarios.\n\nParticipants will:\n\nUndergo an ACG examination in a simulated home environment. Complete an EGD procedure within 24 hours post-ACG ingestion.",[209,29,210,180,181,211],"Gastric Lesion","Upper Gastrointestinal Bleeding (UGIB)","Gastric Neoplasms",[213,184,185,214,215],"upper gastrointestinal diseases","Diagnostic accuracy","Upper Gastrointestinal abnormalities",{"date":217,"type":36},"2025-07-09",{"date":219,"type":36},"2025-03-03",{"date":221,"type":21},"2026-12-31",{"name":195,"class":43},12,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":126,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100588020","helicobacter-pylori-gastritis-and-its-relation-to-metabolic-syndrome-components-100588020","NCT06935955","Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components","Inclusion Criteria:\n\n* Patients aged 18 years and above with dyspeptic symptoms\n\nExclusion Criteria:\n\n* People who have a history of H.Pylori eradication or gastric surgery.\n* Those who have already received anti-cholesterol therapy.\n* Those suffering from severe liver disease, severe kidney disease, or cancer.",{"count":231,"type":21},114,"1 Day","2.2 Aim\n\n1. To evaluate the association between H. pylori infection and the components of metabolic syndrome.\n2. To assess the relationship between the histopathologic features of chronic gastritis evaluated using USS and the components of metabolic syndrome in both H. pylori-positive and H. pylori-negative patients.\n\n2.4. 2- Study Setting: Department of Pathology, Faculty of Medicine, Assiut University.\n\nc. Sample Size Calculation: Sample size was calculated using Epi- Info7. Based on The H. pylori-positive patients were more likely to develop dyslipidemia, and 77.47% of individuals testing positive for H. pylori have higher total cholesterol levels (11). With a confidence limit of 5% and a confidence level of 80%, the minimum number of patients required for this study is 114 cases\n\n2.4.4 -Study tools The study will include 114 patients diagnosed with gastritis in the Gastroenterology unit and scheduled for upper gastrointestinal endoscopy with stomach biopsy. Written informed consent will be obtained from all patients participating in the study.\n\nAll subjects will be asked to complete a medical history questionnaire, followed by a physical examination (height, body weight, waist circumference, and blood pressure) and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, and it will assess chronic and acute gastritis, atrophic gastritis, and metaplasia. The endoscopist will obtain five biopsy samples: two from the antrum, two from the corpus, and one from the incisura.\n\nAll biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two tissue sections will be stained: hematoxylin and eosin (H\\&E) and Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atrophy, and intestinal metaplasia), and each variable will be graded semi-quantitatively.\n\nStatistical analysis using suitable tests will be used to assess our results.\n\n2.4.5 -Research outcome measures:\n\n1. Primary (main): to evaluate the association between H.pylori gastritis and its relation to metabolic syndrome components\n2. Secondary (subsidiary):\n\n2.5-Data management and analysis : Data collection All subjects will be asked to complete a medical history questionnaire, followed by a physical examination (height, body weight, waist circumference, and blood pressure) and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.\n\nComputer software Statistical package for social science (SPSS) program v. 25 (IBM, August 2017).",[29],"2025-04-12",{"date":237,"type":36},"2025-04-20",{"date":239,"type":21},"2025-05-01",{"date":241,"type":21},"2027-05-01",{"name":243,"class":43},"Assiut University"]